Voriconazole therapeutic drug monitoring: focus on safety

Bibliography

• Antoniadou A, Kontoyiannis DP. Status of combination therapy for refractory mycoses. Curr Opin Infect Dis 2003;16:539-45
   PubMed Web of Science ®Google Scholar
• Weber DJ, Peppercorn A, Miller MB, Preventing healthcare-associated Aspergillus infections: review of recent CDC/HICPAC recommendations. Med Mycol 2009;47(Suppl 1):S199-209
   PubMed Web of Science ®Google Scholar
• Trifilio S, Ortiz R, Pennick G, Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35:509-13
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
   PubMed Web of Science ®Google Scholar
• FDA. Voriconazole label information. NDA no. 021266.2008:1-50
   Google Scholar
• Langman LJ, Boakye-Agyeman F. Measurement of voriconazole in serum and plasma. Clin Biochem 2007;40:1378-85
   PubMed Web of Science ®Google Scholar
• Bruggemann RJ, Touw DJ, Aarnoutse RE, International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009;53:303-5
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71
   PubMed Web of Science ®Google Scholar
• Pfizer. VFEND IV (voriconazole) for injection, VFEND tablets, VFEND for oral suspension, Pfizer; 2006
   Google Scholar
• Berge M, Guillemain R, Boussaud V, Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009;11:211-19
   PubMed Web of Science ®Google Scholar
• Leveque D, Nivoix Y, Jehl F, Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274-84
   PubMed Web of Science ®Google Scholar
• Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 1999;47:23-30
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11
   PubMed Web of Science ®Google Scholar
• Machetti M, Zotti M, Veroni L, Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000;2:140-4
   PubMedGoogle Scholar
• Trifilio SM, Yarnold PR, Scheetz MH, Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009;53:1793-6
   PubMed Web of Science ®Google Scholar
• Pascual A, Nieth V, Calandra T, Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007;51:137-43
   PubMed Web of Science ®Google Scholar
• FDA. Background document for the Antiviral Drug Products Advisory Committee Meeting. Voriconazole AC briefing document. Center for Drug Evaluation and Research, Division of Special Pathogen and Immunologic Drug Products; 2001. p. 1-56
   Google Scholar
• Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-44
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Kleinermans D, Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003;56(Suppl 1):17-23
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Shah M, Wynn R, Voriconazole plasma monitoring. Arch Dis Child 2008;93:578-81
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Umemura K, Kondo K, Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75:587-8
   PubMed Web of Science ®Google Scholar
• Wang G, Lei HP, Li Z, The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009;65:281-5
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009;53:935-44
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Ikawa K, Abematsu K, Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009;34:91-4
   PubMed Web of Science ®Google Scholar
• Levin MD, den Hollander JG, van der Holt B, Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother 2007;60:1104-7
   PubMed Web of Science ®Google Scholar
• Das S, Shivaprakash MR, Chakrabarti A. New antifungal agents in pediatric practice. Indian Pediatr 2009;46:225-31
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34
   PubMed Web of Science ®Google Scholar
• Carbonara S, Regazzi M, Ciraci E, Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis. Ann Pharmacother 2009;43:978-84
   PubMed Web of Science ®Google Scholar
• Weiler S, Zoller H, Graziadei I, Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother 2007;51:3459-60
   PubMed Web of Science ®Google Scholar
• Heiz WJ, Kloeser C, Helle A, Higher voriconazole (VRC) serum concentrations in patients with impaired renal function. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, USA, 2009: Abstract A1-587
   Google Scholar
• Ueda K, Nannya Y, Kumano K, Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009;89:592-9
   PubMed Web of Science ®Google Scholar
• Potoski BA, Clarke LG, Venkataramanan R, Clinical risk factors for undetactable voriconazole serum concentrations. 48th Interscience Conference on Antimicrobial Agents and Chemoterapy (ICAAC), Washington, USA, 2008: Abstract M-693
   Google Scholar
• Mulanovich V, Lewis RE, Raad, II, Random plasma concentrations of voriconazole decline over time. J Infect 2007;55:e129-30
   PubMedGoogle Scholar
• Elter T, Sieniawski M, Gossmann A, Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents 2006;28:262-5
   PubMed Web of Science ®Google Scholar
• Henry M, Bolo N, Villafuerte R, MRI voriconazole brain concentrations. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, USA, 2009: Abstract A1-421
   Google Scholar
• Purkins L, Wood N, Ghahramani P, Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53
   PubMed Web of Science ®Google Scholar
• Pakyz A, Bearman G. Adverse drug events complicate antifungal therapy for pulmonary aspergilloma. Consult Pharm 2008;23:804-8
   PubMedGoogle Scholar
• Agrawal AK, Sherman LK. Voriconazole-induced musical hallucinations. Infection 2004;32:293-5
   PubMed Web of Science ®Google Scholar
• Imhof A, Schaer DJ, Schanz U, Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006;136:739-42
   PubMed Web of Science ®Google Scholar
• Zonios DI, Gea-Banacloche J, Childs R, Hallucinations during voriconazole therapy. Clin Infect Dis 2008;47:e7-10
   PubMed Web of Science ®Google Scholar
• Tan K, Brayshaw N, Tomaszewski K, Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46:235-43
   PubMed Web of Science ®Google Scholar
• den Hollander JG, van Arkel C, Rijnders BJ, Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006;57:1248-50
   PubMed Web of Science ®Google Scholar
• Philips JA, Marty FM, Stone RM, Torsades de pointes associated with voriconazole use. Transpl Infect Dis 2007;9:33-6
   PubMed Web of Science ®Google Scholar
• Peman J, Salavert M, Canton E, Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag 2006;2:129-58
   PubMedGoogle Scholar
• Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001;26:648-53
   PubMed Web of Science ®Google Scholar
• Boyd AE, Modi S, Howard SJ, Adverse reactions to voriconazole. Clin Infect Dis 2004;39:1241-4
   PubMed Web of Science ®Google Scholar
• Vanacker A, Fabre G, Van Dorpe J, Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 2008;8:877-80
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:24-34
   PubMed Web of Science ®Google Scholar
• Howard SJ, Hope WW. Antifungal therapeutic drug monitoring for invasive aspergillosis. In: Pasqualotto AC, editor. Aspergillosis: from diagnosis to prevention. Springer; 2009. In press
   Google Scholar
• de Araujo BV, da Silva CF, Haas SE, Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats. Int J Antimicrob Agents 2009;33:154-9
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Thallinger C, Poppl W, Concentrations of voriconazole in healthy and inflamed lung in rats. Antimicrob Agents Chemother 2009;53:2684-6
   PubMed Web of Science ®Google Scholar
• Michael C, Teichert J, Preiss R. Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008;865:74-80
   PubMed Web of Science ®Google Scholar
• Chhun S, Rey E, Tran A, Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852:223-8
   PubMed Web of Science ®Google Scholar
• Pennick GJ, Clark M, Sutton DA, Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003;47:2348-50
   PubMed Web of Science ®Google Scholar
• Shah VP, Midha KK, Findlay JW, Bioanalytical method validation–a revisit with a decade of progress. Pharm Res 2000;17:1551-7
   PubMedGoogle Scholar
• Khoschsorur G, Fruehwirth F, Zelzer S. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob Agents Chemother 2005;49:3569-71
   PubMed Web of Science ®Google Scholar
• Gordien JB, Pigneux A, Vigouroux S, Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal 2009;50:932-8
   PubMed Web of Science ®Google Scholar
• Gage R, Stopher DA. A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal 1998;17:1449-53
   PubMed Web of Science ®Google Scholar
• Pragst F, Herzler M, Herre S, UV spectra of toxic compounds. Berlin; 2007
   Google Scholar
• Pragst F, Herzler M, Erxleben BT. Systematic toxicological analysis by high-performance liquid chromatography with diode array detection (HPLC-DAD). Clin Chem Lab Med 2004;42:1325-40
   PubMed Web of Science ®Google Scholar
• Zhou L, Glickman RD, Chen N, Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002;776:213-20
   PubMed Web of Science ®Google Scholar
• Keevil BG, Newman S, Lockhart S, Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2004;26:650-7
   PubMed Web of Science ®Google Scholar
• Vogeser M, Schiel X, Spohrer U. Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2005;43:730-4
   PubMed Web of Science ®Google Scholar
• Perea S, Pennick GJ, Modak A, Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother 2000;44:1209-13
   PubMed Web of Science ®Google Scholar
• Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997;691:441-8
   PubMed Web of Science ®Google Scholar
• Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008;28:719-29
   PubMed Web of Science ®Google Scholar